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Abstract
Background: Nasopharyngeal carcinoma (NPC) is related to Epstein-Barr virus
(EBV) in endemic areas; however, the role of viruses in nonendemic countries is
unclear. Our nationwide study investigated the prevalence and prognostic signifi-
cance of EBV and human papillomaviruses (HPVs) in Finnish NPC tumors.
Methods: We analyzed samples from 150 patients diagnosed between 1990 and
2009. Viral status was determined using EBV and HPV RNA in situ hybridiza-
tions, and p16 immunohistochemistry. Patient and treatment characteristics were
obtained from patient records.
Results: In our white patient cohort, 93 of 150 (62%) patients were EBV-positive
and 21/150 (14%) patients were HPV-positive with no coinfections. Thirty-six
(24%) tumors were negative for both viruses. The 5-year disease-specific survival
for patients with EBV-positive, HPV-positive, and EBV/HPV-negative tumors was
69%, 63%, and 39%, respectively. In multivariable-adjusted analysis, overall sur-
vival was better among patients with EBV-positive (P = .005) and HPV-positive
(P = .03) tumors compared to patients with EBV/HPV-negative tumors.
Conclusions: In our low-incidence population, EBV and HPV are important prog-
nostic factors for NPC.
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1 | INTRODUCTION
The development of new immunomodulating therapies has
increased interest in the infectious causes of cancer. World-
wide, it is estimated that 10% of newly diagnosed cancers are
attributable to viral infections,1 and according to the Interna-
tional Agency for Research on Cancer (IARC), the
Epstein-Barr virus (EBV) and high-risk human papillomavi-
ruses (HPV) have been classified as group 1 (well-established)
carcinogenic agents in humans.2 EBV is etiologically linked to
Burkitt's lymphoma, extranodal NK/T-cell lymphoma (nasal
type), Hodgkin lymphoma, nasopharyngeal carcinoma (NPC),
and lymphoepithelioma-like carcinoma.3 Presumably, a specific
combination of an EBV variant and a particular human
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leukocyte antigen type is needed for proliferating epithelial
cells to escape immune control.4,5 This hypothesis may par-
tially explain the remarkable geographical differences in the
incidence of NPC. In endemic areas of South-Eastern China,
age-adjusted incidence may reach more than 30 per 100000
persons per year,6 whereas in nonendemic Northern Europe,
the incidence is only 0.4 per 100000 in males and 0.2 per
100000 in females.7 Distribution of the histological subtypes of
NPC and supposed etiological factors also differ between geo-
graphical regions. According to the WHO classification of head
and neck tumors, NPC is subdivided into 3 major types: kerati-
nizing squamous cell carcinoma (KSCC), non-keratinizing car-
cinoma (NKC), and basaloid squamous cell carcinoma.8 NKC
can be further subdivided into differentiated and undifferen-
tiated types.8 In high-incidence endemic areas, up to 99.6% of
NPC tumors display the NKC subtypes, which are more con-
sistently associated with EBV positivity than KSCC.9,10 By
contrast, in low-incidence nonendemic areas, the prevalence of
the NKC subtypes is distinctly lower, whereas the prevalence
of KSCC is higher than in endemic areas.10,11
High-risk HPV infection has been suggested to be one of
the etiological factors causing NPC in whites.12 Studies from
both endemic and nonendemic regions have reported the occur-
rence of HPV in NPC tumors, with or without the coexistence
of EBV.13–31 Unlike in oropharyngeal carcinoma,32 no statisti-
cal significance for outcome has been attributed to HPV in
NPC with 1 exception: Dogan et al. reported that patients with
HPV-positive tumor had, similarly to the patients with EBV-
positive tumor, significantly better overall survival (OS) than
the patients with EBV/HPV-negative tumor.13–31 In addition,
Jiang et al. suggested that although overexpression of p16 is
not a significant prognostic marker for OS in NPC, it correlates
with better progression-free survival and locoregional control
in patients with EBV-positive tumor.22
Previous studies on viral infections in NPC have mainly
reported on small and heterogeneous series of patients treated
at 1 or 2 institutions. Thus, data on the prognostic value of
EBV and HPV in NPC are limited. The aim of this retrospec-
tive whole population-based study was to describe the status of
EBV and HPV in Finnish NPC cases and relate them to histo-
pathological NPC subtypes and patient survival.
2 | PATIENTS AND METHODS
2.1 | Patients
In a nationwide search for the years 1990 to 2009, a total of
207 patients with newly diagnosed primary NPC were iden-
tified from the files of the Finnish Cancer Registry.33 All
patients had biopsies taken from their tumor at the time of
diagnosis, and histological slides stained with hematoxylin
and eosin were available for 168 patients. These specimens
were re-reviewed by an experienced head and neck patholo-
gist (I.L.) to reclassify the cases according to the fourth
edition of the WHO histological classification.8 Formalin-
fixed paraffin-embedded (FFPE) tissue samples were
obtained for 150 patients of the study population. Clinical
records were collected from 5 university hospitals and 3 other
major hospitals in Finland for patient characteristics, presen-
tation of the disease, treatment, and follow-up. All tumors
were confirmed to originate from the nasopharynx. The clin-
ical stage of the disease was determined according to the
International Union Against Cancer (UICC) staging system,
seventh edition.34 Dates and causes of death were acquired
from the Finnish Cancer Registry and Statistics Finland. The
study was approved by the Research Ethics Committee of
the Hospital District of Southwest Finland, National Institute
for Health and Welfare (THL), and National Supervisory
Authority for Welfare and Health (Valvira).
2.2 | Tissue microarray construction
Tissue microarrays (TMAs) were constructed using an auto-
mated tissue microarrayer (TMA Grand Master; 3D Histech
Ltd, Budapest, Hungary) to create 5 new paraffin blocks
from representative 1 mm core samples (n = 324) taken
from the original FFPE blocks of the tumors. Each patient
was represented in the array by at least 1 core, usually
2. Scores from the duplicate cores were averaged to produce
a single score. Five of the original tumor specimens were
derived from neck metastases, whereas the remaining
145 were from the primary tumors. The TMAs also included
control tissues from the liver and the placenta.
2.3 | In situ hybridizations for EBV-encoded RNA and
HPV DNA
Sections with the thickness of 5 μm were cut from the TMA
blocks with a microtome, transferred onto glass slides and
incubated for 2 hours at 58C. For EBV RNA and HPV
DNA detection, chromogenic in situ hybridization (ISH)
was performed using automated Benchmark XT system
(Ventana/Roche Medical Systems Inc., Tucson, Arizona).
The Ventana EBER probe detects early RNA transcripts of
EBV. In the automated process, deparaffinization and pro-
teolytic treatment with Protease 3 (28 minutes) were fol-
lowed by hybridization with the EBV-encoded RNA
(EBER) probe at 57C for 1 hour and counterstaining with
red stain. Positive hybridization was defined as strong dif-
fuse signals in the nucleus of nearly all (>90%) tumor cells.
The Ventana HPV III Family 16 probe was used to detect
high-risk HPV genotypes 16, 18, 31, 33, 35, 39, 45, 51,
52, 56, 58, and 66. In the automated process, deparaffiniza-
tion and proteolytic treatment with Protease 3 (20 minutes)
were followed by hybridization with the HPV probe in 52C
for 2 hours and counterstaining with red stain. Positive stain-
ing for HPVs was recognized as dark blue granules in the
nuclei of neoplastic cells. Stainings were interpreted by a
pathologist (I.L.) blinded to clinical data.
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2.4 | ISH for high-risk HPV E6/E7 mRNA
RNA ISH for high-risk HPV E6/E7 mRNA was performed
manually using the RNAscope 2.5 HD Reagent kit
(Advanced Cell Diagnostics, Inc., Hayward, California)
according to the manufacturer’s protocol. FFPE TMA sec-
tions of 5 μm were incubated for 1 hour at 58C. After
deparaffinization, the sections were pretreated with hydrogen
peroxidase for 10 minutes at room temperature. Target
retrieval was performed for 15 minutes at 100C. The sec-
tions underwent protease treatment (RNAscope Protease
Plus) for 30 minutes at 40C in a hybridization oven fol-
lowed by hybridization with a high-risk HPV 18 cocktail
probe for genotypes 16, 18, 26, 31, 33, 35, 39, 45, 51, 52,
53, 56, 58, 59, 66, 68, 73, and 82 for 2 hours at 40C in a
hybridization oven. Preamplifiers and amplifiers were
hybridized consecutively, accompanied with chromogenic
signal detection with diaminobenzidine (DAB). Finally, the
slides were counterstained with hematoxylin. An endoge-
nous housekeeping gene HS-PPIB probe was used as a posi-
tive control and a bacterial gene DapB probe as a negative
control. The staining was examined (by S.S.) using a qualita-
tive scoring system: a positive staining was recognized as
weak or strong intensity of dot-like nuclear and cytoplasmic
signals in at least 10 cells.
2.5 | Immunohistochemistry for p16
Immunohistochemical (IHC) stains were performed on
3.5-μm thick TMA sections using the automated Benchmark
XT system (Ventana/Roche). For detection of p16 protein,
after deparaffinization and epitope retrieval with CC1 buffer
for 60 minutes, the sections were incubated for 16 minutes
with a mouse monoclonal antibody against p16 protein
(clone E6H4; Ventana/Roche). To visualize the p16 anti-
bodies, a Ventana UltraView Universal DAB Detection Kit
was used, and the sections were counterstained with hema-
toxylin and Bluing Reagent. Positive p16 expression was
defined as strong diffuse nuclear and cytoplasmic staining in
75% or more of tumor cells.
2.6 | HPV genotyping polymerase chain reaction
DNA was extracted from 3 to 5 sections cut from FFPE sec-
tions (total area of the sample was approximately 1 cm2)
using high salt method as described previously.35 DNA was
amplified with primer sets 1 and 2 from the Multiplex HPV
Genotyping Kit (DiaMex GmbH, Heidelberg, Germany).
Primer set 2 (DNA quality control primers) contains primers
to amplify ß-globin gene fragments to verify the amount and
the quality of human genomic sample DNA. A negative con-
trol contained no genomic DNA to confirm the absence of
contamination in the amplification reactions. The labeled
hybrids were analyzed with a Luminex LX-100 analyzer
(Bio-Plex 200 System; Bio-Rad Laboratories, Hercules,
California). The Multiplex HPV Genotyping Kit detects
24 low-risk and high-risk HPV genotypes.
2.7 | Treatment
Patients were treated with radiotherapy (RT) with or without
concurrent chemotherapy (CT) (Table 1). Treatment strate-
gies were somewhat heterogeneous over time, as the study
period covered the shift from definitive RT to chemora-
diotherapy (CRT) protocols and from 3D conformal to
intensity-modulated radiotherapy techniques. However, the
treatment parameters, such as the doses of RT and CT and
the duration of treatment, were consistently similar among
all histological tumor subgroups. The most common sched-
ule was 2 Gy daily fractions 5 times per week; however,
8 patients (5%) received hyperfractionated accelerated RT
with 1.6 Gy twice daily and a planned interim break of about
11 days.36 For all patients, the median dose was 70 Gy in
the nasopharyngeal tumor area, 60 Gy in the involved lymph
nodes, and 50 Gy in the elective neck area. The median
treatment time was 7 weeks. Four patients (3%) were treated
with additional intracavitary brachytherapy, and a second
course of RT for locoregional recurrences was given to
7 (5%) patients. In total, 76 patients (51%) received concur-
rent CT usually with platinum-based (87%) cytostatic drugs.
Furthermore, neoadjuvant CT was given to 10 patients (7%)
and adjuvant CT to 32 patients (21%). A neck dissection was
performed in 17 patients (11%) as part of the primary treat-
ment. Seven patients (5%) with a compromised general con-
dition and/or distant metastases received only palliative
treatment and were omitted from the survival analyses.
2.8 | Statistical analysis
Statistical analyses were carried out using the SAS System for
Windows, release 9.4 (SAS Institute Inc., Cary, North Caro-
lina). Mean ages in the histological subgroups were compared
with the 1-way analysis of variance using the Tukey's method
for pairwise comparisons. Categorical variables between
patients with different viral status were compared with Pear-
son chi-squared test or Fisher's exact test. Survival rates were
calculated using the Kaplan-Meier method. Follow-up time
was calculated from the end of the primary treatment, usually
from the last day of RT, to the end of the follow-up or the date
of death. Age-adjusted and multivariable-adjusted Cox regres-
sion was used to test the association of viral status with
disease-specific survival (DSS) and OS. The multivariable
Cox regression analysis was adjusted for the potential con-
founding factors such as age, sex, smoking, T class, N class,
total RT dose, and treatment (RT vs CRT).33 To avoid multi-
collinearity problems, histology was excluded from the multi-
variable model due to the high correlation with viral status.
The results are expressed using hazard ratios with 95% confi-
dence intervals. P-values of less than .05 were considered as
statistically significant.
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3 | RESULTS
3.1 | Overall characterization of the patients
Analyses were restricted to 150 patients with tissue speci-
mens appropriate for TMA. The demographic and clinical
characteristics are shown in Table 1. The mean age (SD) of
patients was 57.0 (15) years. A total of 145 of 150 (97%)
patients were whites of Finnish ethnic background, and
101 of 150 (67%) patients were men. Thirty-three patients
(22%) had KSCC, and 25 patients (17%) had non-
keratinizing differentiated carcinoma (NK-D), whereas
92 patients (61%) had non-keratinizing undifferentiated car-
cinoma (NK-U) (Table 2). There were no basaloid SCCs.
Smoking was frequent and two-thirds of the patients
(71/107, 66%) with known history were current or ex-
smokers. The percentages of known smokers were 68, 57,
and 69 in KSCC, NK-D, and NK-U, respectively. Unfortu-
nately, smoking history was unknown for almost one-third
of the study population (43/150, 29%). The majority of
patients (63%) were seen with locoregionally advanced
(stage III/IV) disease at the time of diagnosis.
3.2 | EBV and HPV status and disease characteristics
All tumors showing a positive EBER ISH (Figure 1F) reac-
tion were regarded as EBV-positive. For HPV positivity, we
determined that the sample should be positive for both p16
IHC and HPV DNA/RNA ISH (Figure 1E, H, G) or/and
HPV polymerase chain reaction (PCR). We performed HPV
DNA and RNA ISH on all 150 samples but HPV genotyping
only for p16-positive samples. Among the 21 p16-positive
cases, 18 had sufficient FFPE sample for DNA extraction.
Overall, in 93 of 150 (62%) patients, the tumors were
positive for EBV and negative for HPV (EBV-positive
group); in 21 of 150 (14%) patients, they were positive for
HPV and negative for EBV (HPV-positive group); and in
36 of 150 (24%) patients, they were negative for both EBV
and HPV (EBV/HPV-negative group) (Table 2). None of the
patients had a coinfection with both EBV and HPV. Among
the p16-positive tumors, only 1 tumor remained negative for
HPV DNA with both ISH and HPV genotyping methods
(1/21, 5%). Interestingly, this case was confirmed HPV-
positive with the HPV RNA ISH method. In contrast, 16 of
21 (76%) p16-positive tumors were positive in HPV DNA
ISH; in 16 of 18 (89%) p16-positive tumors available for
HPV genotyping method, HPV DNA was amplified with
PCR. There were 3 negative cases in HPV DNA ISH but
positive in HPV DNA PCR, and 1 case that was negative in
HPV DNA PCR but positive in HPV DNA ISH. All
TABLE 1 Patient characteristics stratified according to viral status
Characteristics
No. of patients (%)
All
EBV-
positive
HPV-
positive
EBV/HPV-
negative
Total number 150 (100) 93 (62) 21 (14) 36 (24)
Sex
Male 101 (67) 69 (74) 16 (76) 16 (44)
Female 49 (33) 24 (26) 5 (24) 20 (56)
Age at diagnosis (y)
Mean (SD) 57.0 (15) 54.5 (15) 56.9 (13) 63.5 (15)
Range 12-85 12-82 30-79 21-85
Ethnicity
Finnish 145 (97) 88 (95) 21 (100) 36 (100)
Othera 5 (3) 5 (5) 0 (0) 0 (0)
Smoking
Smoker or ex-smoker 71 (47) 43 (46) 12 (57) 16 (45)
Nonsmoker 36 (24) 25 (27) 3 (14) 8 (22)
Not known 43 (29) 25 (27) 6 (29) 12 (33)
T classification
T1 54 (36) 40 (43) 3 (14) 11 (31)
T2 40 (27) 28 (30) 6 (29) 6 (17)
T3 26 (17) 11 (12) 4 (19) 11 (31)
T4 30 (20) 14 (15) 8 (38) 8 (22)
N classification
N0 53 (35) 35 (38) 4 (19) 14 (39)
N1 33 (22) 20 (22) 8 (38) 5 (14)
N2 51 (34) 30 (32) 8 (38) 13 (36)
N3a 10 (7) 6 (6) 1 (5) 3 (8)
N3b 3 (2) 2 (2) 0 (0) 1 (3)
Overall stage
I 19 (13) 15 (16) 1 (5) 3 (8)
II 37 (25) 27 (29) 5 (24) 5 (14)
III 52 (35) 30 (32) 6 (28) 16 (44)
IV 42 (28) 21 (23) 9 (43) 12 (33)
Treatment
Radiotherapy 67 (45) 46 (49) 7 (33) 14 (39)
Chemoradiotherapy 76 (51) 45 (48) 12 (57) 19 (53)
Palliative 7 (5) 2 (2) 2 (10) 3 (8)
Irradiation technique
2-dimensional
radiotherapy
15 (10) 11 (12) 1 (5) 3 (8)
3-dimensional
radiotherapy
88 (60) 55 (59) 11 (52) 22 (61)
Intensity-modulated
radiotherapy
44 (30) 26 (28) 9 (43) 9 (25)
Abbreviations: EBV, Epstein–Barr virus; HPV, human papillomavirus.
a Three from South-East Asia, 1 from Africa, and 1 from Eastern Europe.
TABLE 2 Relationship between tumor histology according to the WHO
classification and viral status
WHO type
No. of patients (%)
All
EBV-
positive
HPV-
positive
EBV/HPV-
negative
Keratinizing SCC 33 2 (6) 12 (36) 19 (58)
Non-keratinizing
differentiated
25 13 (52) 3 (12) 9 (36)
Non-keratinizing
undifferentiated
92 78 (85) 6 (6) 8 (9)
Total 150 93 (62) 21 (14) 36 (24)
Abbreviations: EBV, Epstein–Barr virus; HPV, human papillomavirus; SCC,
squamous cell carcinoma.
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p16-positive tumors showed positivity in HPV RNA ISH.
HPV genotyping was performed for 18 p16-positive sam-
ples: HPV16 was the most prevalent genotype (11/18, 61%)
followed by HPV18 (2/18, 11%). In addition, HPV11,
HPV33, and HPV59 were present in 1 sample each.
The incidences of EBV or HPV did not vary over the
20-year period of the study. The patients with EBV-positive or
HPV-positive tumors were younger than the patients with
EBV/HPV-negative tumors with mean (SD) ages of 54.5
(15) years for EBV-positive, 56.9 (13) years for HPV-positive,
and 63.5 (15) years for patients with EBV/HPV-negative
tumors. The age difference was statistically significant in the
patients with EBV-positive tumors but not in the patients with
HPV-positive tumors compared to the patients with
EBV/HPV-negative tumors (P = .007 and P = .24, respec-
tively). There were significantly more women in the
EBV/HPV-negative group (56%) compared to the EBV-
positive (26%, P = .001) and the HPV-positive (24%,
FIGURE 1 Histopathological subtypes of nasopharyngeal carcinoma observed in the study (A-C). A, Keratinizing squamous cell carcinoma. B, Non-
keratinizing carcinoma, differentiated type. C, Nonkeratinizing carcinoma, undifferentiated type. D, Negative control for HPV DNA in situ hybridization.
A-H, Magnification ×250. EBV, Epstein-Barr virus; HPV, human papillomavirus; E, Immunohistochemical staining for p16. F, EBV RNA in situ
hybridization (EBER). G, HPV E6/E7 mRNA in situ hybridization. H, HPV DNA in situ hybridization
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P = .020) groups. Table 2 shows the distribution of EBV- and
HPV-positive carcinomas in relation to histological subtypes
(P < .0001). More than one-third of KSCC tumors (12/33,
36%) were HPV-positive, whereas HPV was only detected in
3 of 25 (12%) NK-D tumors and in 6 of 92 (6%) NK-U tumors.
In contrast, the majority of non-keratinizing tumors were EBV-
positive (91/117, 78%), whereas only 2 of 33 (6%) of KSCCs
presented with EBV positivity. Considering the extent of the
disease at the time of diagnosis, EBV-positive tumors showed
a significantly smaller T classification than the EBV/HPV-
negative tumors (P = .030). However, no statistically signifi-
cant differences were found between EBV or HPV status and
N classification, distant metastases, or overall stage.
3.3 | Viral status and clinical outcomes
The median follow-up time was 63 months for patients treated
with curative intent (n = 143). Nearly all patients had a mini-
mum of 5-year follow-up; only 4 survivors were observed after
treatment for fewer than 60 months (49-57 months). Alto-
gether, 67 patients (47%) were seen with a treatment failure,
residual or recurrence. The median latency for overall fail-
ure was 5 months (range, 0-201 months). The patients with
EBV-positive tumors had significantly less local failures
than those who had EBV/HPV-negative tumors (P = .014).
The rate of local failure was 25% in the patients with EBV-
positive, 32% in the patients with HPV-positive, and 49% in
the patients with EBV/HPV-negative tumors, respectively.
There were no statistical differences in nodal, distal, or over-
all failures; however, the patients with EBV/HPV-negative
tumors tended to have more failures than patients in other
groups.
The 5-year DSS for the patients with EBV-positive
tumors was 69%, whereas for the patients with HPV-positive
tumors and with EBV/HPV-negative tumors, it was 63% and
39%, respectively (Figure 2B). In age-adjusted Cox regres-
sion analysis, EBV positivity (P = .007) was a significant
prognostic factor for better DSS compared to EBV/HPV
negativity (Table 3).
The 5-year OS was 66% for the patients with EBV-
positive tumors, 58% for the patients with HPV-positive
tumors, and 27% for the patients with EBV/HPV-negative
tumors (Figure 2A). In age-adjusted Cox regression analysis,
EBV positivity (P < .0001) was a significant prognostic fac-
tor for better OS compared to EBV/HPV negativity (Table 3).
In multivariable-adjusted Cox regression analysis, both EBV
positivity (P = .005) and HPV positivity (P = .034) were
significant prognostic factors for better OS (Table 3B).
All patients who were p16-positive were also HPV-posi-
tive, and thus their survival was similar as described previ-
ously for HPV positivity.
TABLE 3 Age-adjusted and multivariable Cox regression analysis of 143 patients relative to disease-specific survival and overall survival
Patient survival
Age-adjusted
Multivariable Adjusteda
HR (95% CI) P-value HR (95% CI) P-value
Disease-specific survival
Viral status
EBV-positive vs EBV/HPV-negative 0.45 (0.25-0.80) .007 0.69 (0.33-1.44) .32b
HPV-positive vs EBV/HPV-negative 0.50 (0.21-1.20) .12b 0.44 (0.16-1.17) .10b
Overall survival
Viral status
EBV-positive vs EBV/HPV-negative 0.38 (0.23-0.61) <.0001 0.44 (0.25-0.78) .005
HPV-positive vs EBV/HPV-negative 0.61 (0.31-1.20) .15b 0.45 (0.21-0.94) .03
Abbreviations: CI, confidence interval; EBV, Epstein-Barr virus; HPV, human papillomavirus; HR, hazard ratio.
a Adjusted for age, sex, smoking, T classification, N classification, total radiotherapy dose, and treatment.
b Nonsignificant P-value.
FIGURE 2 A, Overall survival and (B) disease-free survival for different
viral statuses. EBV, Epstein-Barr virus; HPV, human papillomavirus
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4 | DISCUSSION
This study focused on the prognostic value of EBV and
HPV status in the NPC tumors of 150 Finnish patients diag-
nosed during 1990 to 2009. To our knowledge, this is the
first nationwide study and one of the largest studies pub-
lished to date of EBV and/or HPV status and their impact on
the outcome of NPC. It is widely accepted that EBV is etio-
logically associated with NPC in high-incidence endemic
regions, such as South-Eastern China, but its significance in
low-incidence nonendemic countries has been equivocal.10
A recent meta-analysis based on 8 studies of NPC in low-
incidence regions including the United States, the United
Kingdom, Greece, and Denmark revealed that the prevalence
of EBV positivity ranged from 0% to 83%, with an average
of approximately 42% in solely white patients.31 In our
nationwide series of Finnish patients with NPC, of which
97% were of white origin, EBV was detected in 62% of their
tumors. Importantly, our study indicated that EBV is a sig-
nificant favorable prognostic factor of NPC in Finland. We
found that both 5-year DSS and OS were significantly better
in the EBV-positive patient group compared to the
EBV/HPV-negative patient group (Figure 2). Our results are
in line with other reports from low-incidence areas indicat-
ing that patients with EBV-positive NPC tumors fare signifi-
cantly better than patients with EBV-negative tumors.13,28,30
High prevalence of HPV positivity has been reported in
NPC tumors in nonendemic areas, but its prognostic signifi-
cance remains unclear. Recent studies from the United States
and the United Kingdom examined tumor samples from 30 to
88 patients using HPV DNA ISH and/or PCR, and reported
HPV positivity ranging from 6% to 30%.13,25,27–29 Only a few
studies have assessed the association of HPV status and disease
outcome, and mostly they have not found statistically signifi-
cant differences in survival between patients with HPV-positive
and HPV-negative tumors.13,20,27–29 In our study, HPV was
detected in 14% of all cases. We used a HPV E6/E7 mRNA
ISH method,37 detecting transcriptionally active high-risk HPV
mRNA, which has not been used in NPC studies before. In
contrast to other studies,13,20,27,29 the patients with HPV-posi-
tive tumors of our cohort showed better survival than the
patients with HPV-negative tumors: in multivariable-adjusted
Cox regression analysis, the patients with HPV-positive tumors
showed significantly better OS compared to the patients with
EBV/HPV-negative tumors. Moreover, Kaplan-Meier analysis
indicated better DSS for the patients with HPV-positive tumors
compared to the patients with EBV/HPV-negative tumors,
although the difference was not statistically significant. We
assume that this lack of statistical significance might be due to
the low number of patients in the HPV-positive group.
The absence of coinfections with EBV and HPV is inter-
esting and might reflect mutually exclusive pathogenetic
mechanisms. Histologically, our EBV-positive tumors were
almost exclusively NKCs in line with prior findings from
endemic and nonendemic areas.10 In contrast, less than half
of all HPV-positive tumors (43%) had non-keratinizing his-
tology, whereas the majority were KSCCs. Due to our whole
population-based patient material, the latter result introduces
new data on the histological distribution of HPV-positive
NPC. Additional studies are needed in both nonendemic and
endemic regions to clarify the role of HPV in the pathogene-
sis of NPC.
HPV-associated NPC bears some resemblance to oro-
pharyngeal SCC (OPSCC) as patients with HPV-associated
OPSCC also have better survival than their HPV-negative
counterparts.38 However, the incidence of HPV-associated
OPSCC has increased since the early 1970s,39 whereas no
rise in the incidence of NPC or HPV-associated NPC was
seen in our cohort during the 20-year period of 1990-2009.
Due to the presence of high-risk HPV in 14% of our cases,
we look forward to learning if HPV vaccines show efficacy
in preventing HPV-positive NPC, as has been the case in
cervical cancer. 40 Possible presence of HPV in NPC may
challenge current diagnostic work-ups, as one must consider
NPC in addition to OPSCC as a possible primary tumor in
cases of HPV-positive neck metastasis. This may also have
direct consequences to the irradiated volume in cases of
HPV-positive metastasis from an unknown primary.
We used a sophisticated HPV E6/E7 mRNA ISH method
to detect transcriptionally active high-risk HPV in NPC sam-
ples.37 The results were fully consistent with IHC detection
of p16 overexpression, as all of the p16-positive tumors in
our study were also positive in HPV E6/E7 mRNA ISH.
Conversely, high-risk HPV mRNA was not identified in
p16-negative samples. This is an important finding, suggest-
ing that p16 is a useful surrogate marker for identifying
HPV in NPC. Nevertheless, due to high specificity, the HPV
E6/E7 mRNA ISH is a recommended method for detecting
high-risk HPV.37 To identify HPV genotype distribution, we
used PCR and multiplex genotyping. We found that HPV16
was the most prevalent genotype (61%) and HPV18 was the
second most prevalent, in line with prior results on other
HPV-associated head and neck malignancies.41
This study carries the limitations of a retrospective study:
for example, patient information on smoking habits and
alcohol use was often incomplete or absent. This limits the
potential to evaluate the outcome data. Furthermore, the
treatment strategies of our patients have been somewhat
inconsistent across the various hospitals without regard to
viral status. However, the strengths of this study include a
whole population-based representation of patients with NPC
nationwide in 1 country during a 20-year study period. The
Finnish Cancer Registry, population statistics, and the uni-
form nationwide health care system enabled nearly full cov-
erage of patients treated for NPC.42 A high proportion of all
diagnostic histopathological samples were retrieved and
usable for TMA (150/207 samples). Some samples were dis-
carded from TMA due to their inadequately small size.
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Patients with EBV-associated NPC are potential candi-
dates for new immunotherapies. Indeed, recent clinical trials
have studied therapeutic EBV vaccines and immune-
checkpoint inhibitors in patients with NPC with encouraging
results for antitumor activity.43–45 EBV vaccines have
mainly implied adoptive T-cell therapy with EBV-specific T
cells prepared in vitro for infusion into patients. 43 Studies
on immune-checkpoint inhibitors pembrolizumab and nivo-
lumab have been conducted mostly with patients with EBV-
positive tumors, and therefore more studies are needed to
show possible differences in the effect of immunomodula-
tors related to viral status.44,45 The high proportion of
patients with EBV-positive NPC in our cohort emphasizes
the value of EBER ISH in histopathological diagnosis of
nasopharyngeal tumors and their metastases in low-
incidence areas. In addition, an analysis of cell-free EBV
DNA load in peripheral blood or in nasopharyngeal brush-
ings could help predict recurrences after treatment.46,47 One
quarter of the tumor samples in this study did not reveal
either EBV or HPV positivity, and these patients with virus-
negative NPC had the poorest outcome. It is tempting to
speculate that these tumors might be genetically different
from the virus-positive similar to findings from other HPV-
negative head and neck cancers,48 and thus they might
require more intensive therapy as in HPV-negative oropha-
ryngeal carcinomas.
In conclusion, we found that the majority of Finnish
patients with NPC have viral etiology and almost two-thirds
of the cases associate with EBV and 1 out of 7 with HPV.
The favorable prognosis for virus-associated patient groups
is in line with results from endemic regions. This highlights
the role of radiosensitivity and immunological aspects in
guiding therapeutic approaches. Patients with p16-positive
cervical lymph node metastasis from an unknown primary
tumor may harbor NPC, although p16-positive oropharyn-
geal cancer remains the most common alternative.
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